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Abstract
Introduction: The aim of this study was to define the reference intervals (RIs) in a Turkish population living in Northeast Turkey (Erzurum) for 34 
analytes using direct and indirect methods. In the present study, the regional RIs obtained were compared with other RI studies, primarily the nati-
onwide study performed in Turkey.
Materials and methods: For the direct method, 435 blood samples were collected from a healthy group of females (N = 218) and males (N = 217) 
aged between 18 and 65 years. The sera were analysed in Ataturk University hospital laboratory using Roche reagents and analysers for 34 analytes. 
The data from 1,366,948 records were used to calculate the indirect RIs using a modified Bhattacharya method.
Results: Significant gender-related differences were observed for 17 analytes. There were also some apparent differences between RIs derived from 
indirect and direct methods particularly in some analytes (e.g. gamma-glutamyltransferase, creatine kinase, LDL-cholesterol and iron). The RIs deri-
ved with the direct method for some, but not all, of the analytes were generally comparable with the RIs reported in the nationwide study and other 
previous studies in Turkey.There were large differences between RIs derived by the direct method and the expected values shown in the kit insert 
(e.g. aspartate aminotransferase, total-cholesterol, HDL-cholesterol, and vitamin B12). 
Conclusions: These data provide region-specific RIs for 34 analytes determined by the direct and indirect methods. The observed differences in RIs 
between previous studies could be related to nutritional status and environmental factors. 
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Reference intervals (RIs) are very important for the 
interpretation of laboratory test results. RIs can be 
determined in some specified ways, and careful 
determination of RIs by a laboratory is extremely 
important (1). The International Federation of Clini-
cal Chemistry (IFCC) has published several papers 
and recommended that each laboratory should 
have its own reference values and estimate the 
corresponding RIs according to defined proce-
dures (2-4). The Clinical and Laboratory Standards 
Institute (CLSI) published in 2010 the C28-A3 
guideline to describe the recommendations on RIs 
(5). However, the majority of clinical laboratories 
are not able to implement their RIs due to the dif-
ficulty in obtaining sufficient numbers of reference 
individuals from a representative population and 
subpopulations, and the high costs of numerous 
tests to be performed by individual laboratories. 
Thus, in practice, only a few clinical laboratories 
produce their own RIs, while the great majority 
use the RIs reported in literature or in the manu-
facturer’s package inserts. The need to revisit the 
concept of RIs has recently been discussed and at-
tempts have been made to overcome these diffi-
culties through multicenter production of RIs (6) 
and/or using hospital and primary healthcare pa-
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tients and applying different criteria for the detec-
tion of RIs (7).
Multicenter RI determination is a good alternative 
and a very important option for individual labora-
tory RI determination. As common standardiza-
tion and traceability are crucial during production 
of reference values, each step of the pre-analytical, 
analytical and statistical application follows a well-
defined protocol. In recent years, the IFCC Com-
mittee on Reference Intervals and Decision Limits 
(the C-RIDL) has been devoted to the determina-
tion of common or harmonized RIs. Recently, the 
C-RIDL published two papers including a protocol 
and comprehensive standard operating proce-
dures (SOPs) (8) with indications on the utility of a 
panel of sera for the alignment of test results 
among laboratories in multicenter studies (9). The 
requirements for conducting the multicenter 
study, phase by phase, can be summarized as: a 
priori selection of reference subjects (i.e. inclusion-
exclusion criteria, ethnicity and questionnaire), 
clear definition of pre-analytical phase (i.e. blood 
collection, sample proccesing, storage and trans-
portation), clear definition of analytical phase (i.e. 
requirements for central laboratories and mea-
surements, quality control, assay standardization 
and cross-comparison of values), statistical proce-
dures for data analysis and reports of results (i.e. 
validation of data, analyses of sources of variation, 
partitioning criteria and derivation of RI) (8). There-
fore, the global use of comprehensive SOPs and a 
common protocol is probably the most effective 
way to investigate globally applicable, common 
RIs (10). Such a nationwide multicenter RI study 
has been organized and performed in Turkey re-
cently, using Abbott analysers for clinical chemis-
try analyses (11). Our laboratory was one of the 
participants in the nationwide multicenter RI study 
mentioned above (11), and we are currently using 
RIs derived from that study. 
The city of Erzurum is located in Northeastern 
Anatolia and has the particular features of an aver-
age altitude of 1800 meters above sea level and 
long, extremely cold winters. Erzurum has a popu-
lation of approximately 800,000 and the popula-
tion is more homogenous than in other regions of 
Turkey. More than half of the population in the re-
gion live in rural areas, and the general economic 
status of the region is relatively low (12). Consider-
ing the importance of additional regional charac-
teristics of the population in Eastern Anatolia and 
the nutritional, environmental, economic and so-
cio-cultural factors, we organized and conducted 
a specific regional RI study in parallel to our par-
ticipation in the nationwide multicenter study. The 
study aimed to (a) define region-specific direct 
and indirect RIs for 34 biochemical analytes and 
(b) explore possible regional differences in direct 
RIs derived from the nationwide multicenter study 
and other RI studies in Turkey. The RIs obtained 
through the direct method were compared with 
the RIs suggested by the manufacturer. The re-
gion-specific RIs were determined using both the 
direct and indirect methods. In the direct method, 
recommended by the IFCC, the RIs were deter-
mined in a healthy reference population from our 
region (Eastern Turkey), selected according to the 
IFCC recommendations. In the indirect method, 
the region-specific RIs were determined using a 
large amount of hospital patient data from our 
laboratory information system according to the 
modified Bhattacharya procedure (13). The modi-
fied Bhattacharya procedure is widely accepted as 
an alternative approach for the determination RIs 
of using the stored patient data. 
Materials and methods
Subjects
For the direct RI determination, a total of 435 (217 
males and 218 females) healthy individuals, select-
ed according to the IFCC recommendations from 
our region (Eastern Turkey), were included in the 
study. The selected individuals were aged be-
tween 18 and 85 years. The main target age range 
was 20–65 years. A questionnaire comprising gen-
eral health and lifestyle questions was completed 
in order to include proper subjects and exclude ir-
relevant subjects to avoid confounding and false 
results. Inclusion and exclusion criteria were set ac-
cording to the IFCC/C-RIDL protocol (8). Exclusion 
criteria were: BMI ≥ 30, alcohol consumption ≥ 70 
g/day, smoking > 20 cigarettes/day, chronic sys-
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temic disease, having an acute disease within the 
last 14 days, currently known carrier state for HBV, 
HBC or HIV, pregnancy, and being in the postpar-
tum first year. The volunteers gave written in-
formed consent to participate in the study and 
they were informed of the results on request.
Methods
The study protocol was approved by the Ethics 
Committee of Ataturk University, School of Medi-
cine (number 2012.4.1/11). In the direct method, 
the reference individuals were selected from a ref-
erence population using specific, well-defined cri-
teria. For the direct method, preparation of the 
subjects for sampling and the procedures of sam-
pling, and sample processing were conducted us-
ing the recently published IFCC/C-RIDL protocol 
(8). Blood specimens of 8 mL were collected into 
gel serum separator tubes, SST II (Becton, Dickin-
son and Company, Oxford, England). The subjects 
fasted prior to sample collection and the time of 
sampling was set at 7 to 10 am. Within 20 to 30 
minutes of sampling, the samples were centri-
fuged at 1200 x g for 10 min at room temperature. 
Blood samples were centrifuged within 20–30 
minutes of withdrawal from each volunteer. One 
aliquot of 1 ml was prepared and stored at -80 ± 2 
oC for up to six months until analysis. The frozen 
serum samples were transferred to a refrigerator 
(+4–6 oC) for about 2–3 hours for thawing before 
analysis and then transferred to the analyser with-
in 6 hours of thawing.
The following analytes were measured in each se-
rum sample: alkaline phosphatase (ALP), gamma-
glutamyltransferase (GGT), aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), lac-
tate dehydrogenase (LDH), amylase (AMY), cre-
atine kinase (CK), triglycerides (TG), total cholester-
ol (TC), high-density lipoprotein cholesterol (HDL-
C), low-density lipoprotein cholesterol (LDL-C), 
calcium (Ca), inorganic phosphate (IP), magnesium 
(Mg), iron (Fe), total protein (TP), albumin (ALB), to-
tal bilirubin (TBIL), direct bilirubin (DBIL), glucose 
(GLU), urea (UN), creatinine (CRE), uric acid (UA), so-
dium (Na), potassium (K), chloride (Cl), free triiodo-
thyronine (FT3), free thyroxine (FT4), thyroid stimu-
lating hormone (TSH), vitamin B12 (VIT B12), folate 
(FOL), ferritin (FER), parathyroid hormone (PTH) 
and insulin (INS). All analyses were performed us-
ing Cobas 8000 and E 170 (Roche Diagnostics, 
Mannheim, Germany) and following the manufac-
turer’s instructions. The test list, assay methods, kit 
versions, calibrators and instrumentation profile 
are summarized in Table 1. The calibrators and 
controls were obtained from Roche (Roche Diag-
nostics, Mannheim, Germany).
For the indirect RI determination, the results of the 
laboratory analyses, stored for approximately one 
year, were used. During this period, approximately 
5 million stored laboratory records of 1,063,605 in-
dividuals (aged 18–65 years old) were evaluated, 
and 1,366,948 refined records, of which 594,753 
belonged to males and 772,195 belonged to fe-
males, were used for statistical analysis. All patient 
results have been stored in the laboratory infor-
mation system, LIS, to constitute the original data-
base. A specific Structured Query Language (SQL) 
was prepared for analyses and exclusions.
Assuming that persons with repeated measure-
ments have a higher chance of being diseased, 
data from subjects who had repeated meaure-
ments for any of the given 34 analytes within the 
3-month observation period were excluded to en-
sure that the majority of the values for each ana-
lyte were health related. Together with this exclu-
sion criterion, data for hospitalized patients and 
for ambulatory patients from the intensive care 
units were eliminated. Thus, the selected popula-
tion can be named as outpatients. 
The same analyser, Cobas 8000 and E 170 (Roche 
Diagnostics, Mannheim, Germany), was used for 
the direct and indirect studies. The time periods 
were the same (between January and December 
2012) and the analytical issues were exactly the 
same in both studies.
Internal quality control was performed by daily as-
says of commercial lyophilized sera in two concen-
trations of each analyte. The desirable limits for 
between- and within-day analytical variations 
(CVA) were set as ½ of within-subject biological 
variation (CVI), as defined by Ricos et al. (14) and re-
ported on the Westgard website (15). The within- 
http://dx.doi.org/10.11613/BM.2016.023 Biochemia Medica 2016;26(2):210–23 
  213
Bakan E. et al. Regional reference interval study in Turkey
Analyte Unit Method N
With-in day CVA Between-day CVA Analytical system / Kit 
Version / Calibrators / 
Calibrators’ traceabilityC1 C2 C1 C2
ALP U/L IFCC, p-Nitrophenyl Phosphate 20 1.20 1.31 2.34 2.57
Roche Cobas 8000 / 2 / CFAS / 
O.F. IFCC
GGT U/L Szasz, gamma- glutamylcar-boxynitroanilid 20 1.12 0.82 1.66 2.08
Roche Cobas 8000 / 2 / CFAS / 
O.F. Persijn / v.d.Slik
AST U/L IFCC, UV without P5P, 37 °C 20 2.01 1.93 2.49 2.24 Roche Cobas 8000 / 1 / CFAS / O.F. IFCC
ALT U/L IFCC, UV without P5P, 37 °C 20 1.68 1.50 2.69 2.45 Roche Cobas 8000 / 1 / CFAS / O.F. IFCC
LDH U/L IFCC, UV Lactate-pyruvate 20 1.04 0.86 1.48 1.46 Roche Cobas 8000 / 2 / CFAS / O.F. IFCC
AMY U/L IFCC, colorimetric PNP 20 0.86 0.93 1.40 1.81 Roche Cobas 8000 / 2 / CFAS / IFCC
CK U/L IFCC, UV NAC activated 20 1.21 1.03 1.46 1.24 Roche Cobas 8000 / 1 / CFAS / O.F. IFCC
TG mmol/L Enzymatic GPO-PAP colorimetric 20 1.80 1.53 2.12 1.92
Roche Cobas 8000 / 1 / CFAS 
/ ID-MS
TC mmol/L Enzymatic CHOD-PAPcolorimetric 20 1.92 1.13 2.33 1.93
Roche Cobas 8000 / 2 / CFAS / 
Abell-Kendall
HDL-C mmol/L Colorimetric (oxidase) 20 1.21 1.12 2.46 1.57 Roche Cobas 8000 / 3 / CFAS Lipids / CDC Reference M.
LDL-C mmol/L Colorimetric (oxidase) 20 2.01 1.89 2.99 2.49 Roche Cobas 8000 / 1 / CFAS Lipids / Beta quantification
Ca mmol/L Ortho – crezolftalein complex 20 0.85 0.89 1.01 1.04
Roche Cobas 8000 / 2 / CFAS / 
SRM 956c
IP mmol/L UV Phosphomolybdate 20 1.05 1.23 2.05 2.53 Roche Cobas 8000 / 2 / CFAS / Primary reference material
Mg mmol/L Clorophosphonase III 20 2.12 1.23 2.61 1.56 Roche Cobas 8000 / 2 / CFAS / Atomic absorption
Fe µmol/L Ferro Zinc 20 0.96 0.92 1.32 1.71 Roche Cobas 8000 / 2 / CFAS / Primary reference material
TP g/L Biuret 20 0.72 0.65 2.03 1.41 Roche Cobas 8000 / 2 / CFAS / SRM 927b
ALB g/L Bromocresol Green 20 0.90 1.06 1.92 1.69 Roche Cobas 8000 / 2 / CFAS / ERM-DA470k / IFCC
TBIL µmol/L Jendrassik-Grof 20 1.70 1.00 1.60 1.26 Roche Cobas 8000 / 3 / CFAS / Doumas
DBIL µmol/L Diazo 20 0.80 0.60 2.10 1.29 Roche Cobas 8000 / 2 / CFAS / Doumas
GLU mmol/L Hexokinase 20 0.90 1.13 1.37 1.65 Roche Cobas 8000/3/CFAS/ID-MS
UN mmol/L UV, urease 20 1.10 1.28 1.38 1.56 Roche Cobas 8000 / 1 / CFAS / SRM 909b
CRE µmol/L Kinetic 20 1.36 1.75 2.30 2.96 Roche Cobas 8000 / 2 / CFAS / ID-MS
UA µmol/L Uricase, colorimetric 20 1.43 1.68 2.38 2.56 Roche Cobas 8000 / 2 / CFAS / ID-MS
Table 1. Analytical and methodological characteristics of analytes with CVA data
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Analyte Unit Method N
With-in day CVA Between-day CVA Analytical system / Kit 
Version / Calibrators / 
Calibrators’ traceabilityC1 C2 C1 C2
K mmol/L Ion Selective Electrode Direct 20 0.90 1.20 1.97 2.16
Roche Cobas 8000 / 2 / CFAS /  
P.C. gravimetrically prepared
Cl mmol/L Ion Selective Electrode Direct 20 1.00 1.30 1.48 1.63
Roche Cobas 8000 / 2 / CFAS / 
P.C. gravimetrically prepared
FT3 pmol/L ECLIA 20 3.34 3.25 3.73 3.91 Roche E170 / 3 / FT3 Calset / FT3 assay (REF 11731386)
FT4 pmol/L ECLIA 20 2.02 2.15 2.44 2.51 Roche E170 / 2 / FT4 Calset / Equilibrium dialysis
TSH mU/L ECLIA 20 2.45 2.66 4.26 4.72 Roche E170 / 1 / TSH Calset / WHO Reference Std.80 / 558
VIT B12 pmol/L ECLIA 20 3.25 3.47 4.82 4.64 RocheE170 / 1 / VITB12 Calset / VITB12 assay (REF1182075)
FOL nmol/L ECLIA 20 3.42 3.64 4.59 4.77 Roche E170 / 3 / FOL Calset / FOLassay (REF03253678)
FER µg/L ECLIA 20 3.24 3.83 5.54 6.61 Roche E170 / 1 / FER Calset / 1st (IS) NIBSC
PTH pmol/L ECLIA 20 2.53 2.82 4.05 4.53 Roche E170 / 1 / PTH Calset / RIA
INS pmol/L ECLIA 20 4.22 4.61 6.62 5.89 Roche E17 / 1 / INS Calset / Reference STD. 66 / 304
CVA – Analytical variation, C1 – Control 1, C2 – Control 2, CFAS – Calibrator for automated systems, CFAS Lipids – Calibrator 
for automated systems of lipids, IFCC – International Federation of Clinical Chemistry and Laboratory Medicine, P5P – 
Pyridoxal-5-phosphate, GPO-PAP – Glycerol phosphate oxidase / peroxidase aminophenazone, CHOD-PAP – Cholesterol oxidase 
/ peroxidase aminophenazone, UV – Ultraviolet, PNP – para-nitrophenol, NAC – N-acetylcysteine, CDC – Centers for Disease 
Control and Prevention, ECLIA – Electro-chemiluminescence immunoassay, SRM – Standard reference material, ERM – European 
reference material, ID-MS – Isotope Dilution-Mass Spectrometry, O.F. – Original formulation, P.C. – Primary calibrators, RIA – 
Radioimmunoassay, (IS) NIBSC – (International Standard) National Institute for Biological Standards and Control, STD – Standard.
Table 1. Analytical and methodological characteristics of analytes with CVA data (continued)
and between-day CVA for all analytes, listed in Ta-
ble 1, did not exceed the desirable limits reported 
(14). External quality control was performed using 
EQAS (Bio-Rad Laboratories, Milano, Italy). The re-
sults of the external quality control were accepta-
ble when compared with the same peer group.
Statistical analysis 
Data obtained by the direct method were trans-
ferred to SPSS version 20.0 (SPSS Inc., Chicago, 
USA) and MedCalc version 14.12.0 (MedCalc Soft-
ware, Mariakerke, Belgium) to calculate RIs. Refer-
ence limits define the central 95% of the reference 
population. Nonparametric statistic was used for 
the estimation of the direct RIs. Nonparametric 
methods typically encompass the central 95th 
percentile of reference values and use the 2.5th 
and 97.5th percentile as the lower and upper refer-
ence limit, respectively. Dixon’s range test, recom-
mended by the IFCC for statistical analysis in refer-
ence interval studies, was used to detect and elim-
inate extreme values as outliers. Dixon’s outlier 
range statistic typically identifies the single most 
extreme value at the upper or lower limit as an 
outlier (16). The simplest criterion of rejection (r cri-
teria) is D/R > 0.3, where D is the absolute differ-
ence between the most extreme value and the 
next nearest value divided by the range of all val-
ues (R) including the extreme value (s). Confidence 
intervals of 90% (90% CI) of reference limits were 
estimated following IFCC recommendations (4). 
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The magnitude of the standard deviations (SD) of 
test results between-gender (SD-gender) varia-
tions were computed by three-level nested ANO-
VA. A standard deviation ratio (SDR) greater than 
0.3 was regarded as a guide to consider partition-
ing reference values by the factor (17).
A modified Bhattacharya procedure (13) was used 
to estimate the indirect RIs from hospital patient 
data. In the unmodified Bhattacharya method, the 
distribution of the main population is assumed to 
be Gaussian (18). Since most laboratory data are 
not Gaussian, Baadenhuijsen et al. described a 
modification (13). The data of the total unselected 
hospital population obviously cannot be trans-
formed to a normal distribution because the devi-
ation from the normal distribution is caused in 
part by results that are pathological. Only the ana-
lytical data near the mean were used (at least 40% 
of the results). It was assumed that calculation on 
this subpopulation was not influenced by patho-
logical test results (13). The 90% CI of the lower 
and upper limits of the RIs were calculated using 
the bootstrap method, through random resam-
pling (200 times) of the same dataset. 
For each analyte, the values of both groups of RIs, 
direct and indirect, were calculated for males and 
females, separately. The difference was taken into 
consideration and noted if the difference between 
the lower limits or upper limits was more than 10% 
(> 10%) of the compared RI.
Results
The median (interquartile range, IQR) age of males, 
females and the total group were 38 (29–47), 39 
(29–48) and 38 (29–48) years, respectively. The 
age distribution for the direct population is pre-
sented in Table 2.
Table 3 shows the RIs of 34 analytes determined 
by the direct method in males (N = 217) and fe-
males (N = 218) participants and 90% CIs of refer-
ence limits. Significant gender-related differences 
(SDR > 0.30) were observed for 17 analytes; ALP, 
GGT, AST, ALT, CK, TG, TC, HDL-C, LDL-C, Fe, TBIL, 
UN, CRE, UA, FER, VIT B12 and PTH. However, RIs for 
all analytes were stated as separate RIs for males 
and females (Table 3). The upper limits of RIs de-
termined by the direct method in males were 
higher (> 10%) than in females for GGT, ALT, AST, 
AMY, CK, TG, LDL-C, TBIL, DBIL, CRE, UA, FER and 
INS, and lower (> 10%) than in females for HDL-C, 
FOL and PTH (Table 3). The lower limits of RIs in 
males were higher (> 10%) than females for GGT, 
ALT, AMY, CK, Fe, UN, CRE, UA, FER, TBIL and FT3, 
and the values in females were higher (> 10%) 
than in males for HDL-C, TSH, IP and INS (Table 3). 
The calculated indirect RIs for each analyte and 
90% CIs of reference limits are shown for males 
and females in Table 4. The upper limits of RIs for 
males were higher (> 10%) than in females for CK, 
Fe, TBIL, CRE, UA and FER. The lower limits of RIs 
for males were higher (> 10%) than in females for 
ALP, GGT, CK, TG, Fe, TBIL, DBIL, UN, CRE, UA, VIT 
B12 and FER (Table 4). The lower limits of RIs for 
males were lower (> 10%) than in females for HDL-
C, TC, FT3 and TSH. The upper limits of RIs for 
males were lower (> 10%) than in females for FT3 
and PTH (Table 4).
As seen in Tables 3 and 4, there were some differ-
ences (> 10% lower or higher) in the upper limits 
of the observed RIs for GGT, ALT, LDH, CK, HDL-C, 
LDL-C, Fe, Alb, FT3, FT4 and FER determined by di-
Group N Age, years
Males and females 435 38 (29–48)
Males 217 38 (29–47)
18–29 years 56 27 (24–29)
30–39 years 56 33 (31–37)
40–49 years 55 44 (42–46)
50–64 years 40 54 (51–57)
65–85 years 10 71 (67–76)
Females 218 39 (29–48)
18–29 years 57 27 (23–29)
30–39 years 56 35 (31–38)
40–49 years 55 45 (42–46)
50–64 years 40 53 (51–55)
65–85 years 10 72 (68–78)
Age is expressed as median (interquartile range).
Table 2. Age distribution of participants in the direct RI study
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LL–CI LL–UL UL–CI LL–CI LL–UL UL–CI
ALP U/L 196 31–42 40–127 107–131 206 31–42 40–116 107–130
GGT U/L 210 8–9 9–58 (*, #) 54–60 210 6–8 7–32 30–34
AST U/L 210 8–11 9–28 (*) 24–30 214 8–11 9–24 22–38
ALT U/L 217 9–12 10–55 (*, #) 51–60 218 5–9 6–30 26–42
LDH U/L 217 88–117 104–212 193–220 218 22–112 105–202 185–212
AMY U/L 217 20–36 34–131 (*, #) 118–139 218 9–37 23–116 107–125
CK U/L 217 37–54 42–228 (*, #) 223–232 218 28–39 31–142 135–152
TG mmol/L 210 0.51–0.66 0.59–3.12 (*) 3.03–3.16 213 0.38–0.72 0.63–2.71 2.52–3.08
TC mmol/L 217 2.27–3.14 3.02–6.68 6.42–6.81 218 0.70–3.26 2.90–6.53 6.04–6.74
HDL-C mmol/L 217 0.49–0.65 0.54–1.30 1.24–1.63 218 0.50–0.80 0.72–2.02 1.83–2.09
LDL-C mmol/L 217 1.28–1.71 1.49–4.98 (*) 4.77–5.18 218 0.53–1.74 1.45–4.48 4.27–4.79
Ca mmol/L 217 2.0–2.2 2.1–2.5 2.4–2.6 218 2.0–2.2 2.1–2.5 2.4–2.8
IP mmol/L 217 0.75–0.85 0.76–1.51 1.45–1.54 218 0.73–0.98 0.85–1.39 1.34–1.55
Mg mmol/L 217 0.69–0.72 0.70–0.90 0.86–0.99 218 0.65–0.70 0.68–0.89 0.87–0.93
Fe µmol/L 217 8.1–8.9 8.5–30.1 (#) 29.5–30.4 218 3.6–6.7 5.2–27.8 25.2–30.4
TP g/L 217 58–64 62–79 77–80 218 24–63 62–78 77–79
ALB g/L 217 39–42 42–50 49–51 218 35–40 38–50 48–51
TBIL µmol/L 212 3.7–3.9 3.8–23.9 (*, #) 22.4–24.1 212 3.0–3.2 3.1–20.7 19.8–22.1
DBIL µmol/L 213 1.0–1.3 1.2–5.3 (*) 5.1–5.4 214 0.9–1.2 1.1–4.6 4.5–4.8
GLU mmol/L 217 3.5–3.8 3.7–6.1 6.0–6.2 218 2.9–4.1 3.9–6.3 5.6–6.6
UN mmol/L 217 3.0–3.5 3.1–7.2 (#) 6.5–7.5 218 1.9–2.7 2.3–6.9 6.1–8.1
CRE µmol/L 217 56–66 59–107 (*, #) 98–154 218 39–48 45–83 76–90
UA µmol/L 217 190–227 202–489 (*, #) 458–546 218 120–167 148–369 331–427
Na mmol/L 217 125–137 134–147 146–149 218 132–135 134–146 144–147
K mmol/L 217 3.5–3.9 3.7–5.1 4.9–5.4 218 3.7–4.0 3.8–5.1 5.0–5.3
Cl mmol/L 217 92–99 96–108 107–109 218 96–99 98–108 107–115
FT3 pmol/L 217 3.3–3.9 3.7–6.0 (#) 5.9–7.0 218 2.7–3.6 3.1–6.2 5.9–6.8
FT4 pmol/L 217 10.4–13.3 11.9–20.4 19.4–29.7 218 2.5–12.3 11.3–20.9 19.5–21.9
TSH mU/L 212 0.28–0.40 0.36–4.78 4.22–5.12 211 0.40–0.52 0.49–4.92 4.75–4.95
VIT B12 pmol/L 202 59–79 70–368 321–388 200 56–90 71–395 372–413
FOL nmol/L 215 7–10 9–28 26–33 216 7–11 9–33 29–38
FER µg/L 217 42–49 46–399 (*, #) 355–436 218 13–17 15–209 143–418
PTH pmol/L 217 1.6–2.0 1.8–8.1 6.9–9.2 218 1.6–2.0 1.9–11.9 10.1–23.7
INS pmol/L 212 20–25 21–190 (*) 150–210 208 22–28 26–161 131–176
UL – upper limit. LL – lower limit, CI – confidence interval, (*) – UL of males (> 10%) higher than females, (#) – LL of males higher 
(> 10%) than females.
Table 3. Reference intervals estimated with direct method using non-parametric calculation
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LL–CI LL–UL UL–CI LL–CI LL–UL UL–CI
ALP U/L 19,116 33–37 35–125 (#) 122–128 40,787 30–32 31–118 115–122
GGT U/L 16,871 4–6 5–38 (#) 36–40 22,112 3–5 4–36 35–37
AST U/L 27,941 9–11 10–29 28–31 37,488 9–11 10–28 27–29
ALT U/L 28,260 5–6 5–28 27–30 37,187 4–6 5–26 25–27
LDH U/L 27,217 136–144 140–261 255–266 39,041 136–149 138–260 254–265
AMY U/L 8555 19–21 20–123 120–126 12,276 18–20 19–122 119–125
CK U/L 16,224 21–23 22–173 (*, #) 171–175 15,752 16–18 17–146 144–148
TG mmol/L 24,973 0.27–0.32 0.29–2.85 (#) 2.81–2.88 28,206 0.07–0.16 0.10–2.86 2.83–2.89
TC mmol/L 13,834 2.44–2.57 2.49–7.23 7.13–7.31 15,695 2.69–2.80 2.75–6.97 6.87–7.10
HDL-C mmol/L 16,674 0.49–0.54 0.52–1.57 1.53–1.61 19,303 0.59–0.69 0.64–1.74 1.67–1.81
LDL-C mmol/L 4370 0.98–1.09 1.04–4.09 4.04–4.14 4992 1.00–1.05 1.03–4.22 4.17–4.27
Ca mmol/L 16,304 2.0–2.1 2.1–2.7 2.6–2.8 23,204 2.0–2.2 2.1–2.6 2.5–2.7
IP mmol/L 24,927 0.61–0.68 0.65–1.52 1.45–1.58 36,873 0.61–0.74 0.68–1.52 1.45–1.58
Mg mmol/L 1830 0.62–0.70 0.66–0.95 0.90–0.99 15,394 0.62–0.70 0.66–0.95 0.90–0.99
Fe µmol/L 1296 2.6–2.9 2.8–27.0 (*, #) 26.5–27.4 2774 1.8–2.1 1.9–23.4 22.9–24.0
TP g/L 22,668 60–64 62–84 81–87 29,002 60–66 63–84 81–87
ALB g/L 25,930 32–34 33–59 57–60 33,973 33–38 35–55 53–57
TBIL µmol/L 22,247 3.7–4.1 3.9–23.9 (*, #) 21.9–25.6 29,121 2.5–2.7 2.6–20.7 18.9–22.1
DBIL µmol/L 20,380 1.1–1.3 1.2–5.5 (#) 5.4–5.6 26,334 0.8–1.0 0.9–5.2 4.2–4.3
GLU mmol/L 22,375 3.5–3.7 3.6–6.1 5.9–6.2 29,140 3.6–3.8 3.7–5.9 5.8–6.0
UN mmol/L 18,847 2.7–2.9 2.8–7.6 (#) 7.1–8.2 22,543 1.6–1.8 1.7–7.5 7.1–7.9
CRE µmol/L 22,476 46–51 49–104 (*, #) 101–106 27,329 27–44 35–81 79–84
UA µmol/L 13,492 137–161 149–494 (*, #) 482–506 19,801 83–95 89 -4 46 428–464
Na mmol/L 42,197 133–137 135–146 144–147 51,325 133–137 135–146 144–147
K mmol/L 44,011 3.4–3.7 3.6–5.1 5.0–5.2 52,738 3.4–3.6 3.5–5.1 5.0–5.2
Cl mmol/L 3104 97–99 98–111 110–113 3659 96–100 98–112 110–114
FT3 pmol/L 20,030 1.5–1.8 1.7–5.4 5.3–5.5 21,367 1.5–2.3 2.1–6.2 4.7–6.5
FT4 pmol/L 20,431 9.3–10.2 9.8–25.2 24.9–25.4 21,535 8.9–9.7 9.3–25.2 24.9–25.4
TSH mU/L 19,027 0.30–0.36 0.32–4.43 4.39–4.46 19,636 0.37–0.45 0.42–4.31 3.04–4.4
VIT B12 pmol/L 8846 72–76 75–336 (#) 334–338 9213 55–58 57–314 311–317
FOL nmol/L 6952 4–6 5–29 28–30 7261 4–6 5–29 28–30
FER µg/L 4978 33–56 46–356 (*, #) 342–385 5710 14–25 17–193 181–206
PTH pmol/L 1629 1.4–1.8 1.6–7.8 7.7–7.9 3649 1.3–1.7 1.6–9.0 8.8–9.1
INS pmol/L 6741 8–12 10–179 160–194 7775 8–11 10–177 167–188
UL – upper limit. LL – lower limit, CI – confidence interval, (*) – UL of males (> 10%) higher than females, (#) – LL of males higher 
(> 10%) than females.
Table 4. Reference intervals estimated with indirect method using modified Bhattacharya algorithm
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rect and indirect methods for males and GGT, AST, 
ALT, LDH, HDL-C, Fe, DBIL, UA, FT4, TSH, VIT B12, 
FOL and PTH for females. There were some differ-
ences (> 10% lower or higher) in the lower limits of 
the observed RIs for AST, ALP, GGT, ALT, LDH, AMY, 
CK, TG, TC, LDL-C, IP, Fe, ALB, CRE, UA, FT3, FT4, 
TSH, FOL, PTH and INS for males and ALP, GGT, 
AST, ALT, LDH, AMY, CK, TG, HDL-C, LDL-C, IP, Fe, 
DBIL, TBIL, UN, CRE, UA, FT3, FT4, TSH, VIT B12, FOL, 
FER, PTH and INS for females.
Table 5 includes several categories of data for the 
34 analytes: (a) direct RIs obtained from reference 
individuals according to the IFCC recommenda-
tions of our region, (b) the RIs of three regional 
studies [(R1 (19), R2 (20), and R3 (21)] in Turkey, and 
the RIs of the recently conducted multicenter RI 
study for Turkey (11) and (c) the values expected by 
the manufacturer for these analytes.
The RIs observed in the present study by the direct 
method for some, but not all analytes, were more 
or less comparable with the values reported in the 
MC, R1, R2 and R3 studies (Table 5). The values of 
RIs for some analytes in the present study and the 
multicenter study were comparable. However, the 
upper limits of RIs determined in the multicenter 
study for ALT, CRE and LDL-C. The lower limits of 
RIs determined in the present study for males 
were lower (> 10%) than those of the multicenter 
study for GGT, AST, LDH, CK, HDL-C, Mg and DBIL. 
The upper limits of RIs determined in the present 
study for females were higher (>10%) than those 
of the multicenter study for GGT, ALT, LDL-C, IP, 
CRE, TBIL, TG and GLU. The lower limits of RIs de-
termined in present study for males were higher 
(> 10 %) than those of the the present study for fe-
males were lower (> 10%) than those of the multi-
center study for CRE, TC, HDL-C, AST, ALT, LDH, 
AMY, Mg and DBIL (Table 5).  
The RIs in the lower and/or upper limits observed 
in the present study were also different (> 10 % 
lower or higher) from the values reported in R1 
study for ALP, GGT, AST, ALT, LDH, AMY, CK, TG, 
HDL-C, IP, TBIL, DBIL, GLU, UN, CRE, UA, TSH, VIT 
B12, FOL and FER, and the values reported in R2 
study for ALP, TG, HDL-C, LDL-C, CRE, FT3, FT4 and 
TSH, and the values reported in R3 study for ALP, 
AST, ALT, TG, HDL-C, UN, UA, CRE, K, FT3, FT4, TSH, 
VIT B12, and FOL (Table 5). As seen in Table 5, there 
are some differences (> 10% lower or higher) in 
the lower and/or upper limits of the observed RIs 
for ALP, GGT, AST, ALT, LDH, AMY, CK, TG, TC, HDL-
C, LDL-C, Fe, Mg, TP, ALB, TBIL, DBIL, GLU, FT3, TSH, 
FER, VIT B12, PTH, FOL and INS from the values ex-
pected by the manufacturer for these analytes. 
Discussion
The present data provided direct and indirect RIs 
for 34 biochemical analytes for our laboratory in 
Erzurum in Eastern Anatolia. The results of this 
study showed some differences between the RIs 
derived by the direct method and the indirect 
method. The RIs derived with the direct method 
for some, but not all, of the analytes were compa-
rable with the RIs reported in the nation-wide 
study and other previous studies in Turkey.
The data of the present study showed clearly that 
there are some differences in the lower and/or up-
per limits of the RIs derived from direct and indi-
rect methods in some analytes, such as GGT, ALT, 
TG, TC, HDL-C, LDL-C, ALB, Fe, UA, FT3, FT4, and VIT 
B12. ALB and UA have a wider RI in the indirect 
method when compared to the direct method. 
Results similar to those for ALB have been ob-
served for UA, where the lower limit is lower in the 
indirect method. Another analyte, with higher up-
per limits in the direct method is VIT B12. Others, 
such as GGT, ALT and CK have a narrower RI in the 
indirect method when compared to the direct 
method. The differences between the results can 
be attributed in part to different statistical meth-
ods (Bhattacharya and IFCC methods), and in part 
to differences between populations (hospital and 
healthy populations). With some limitations, the 
Bhattacharya method can be of help in the deter-
mination of reference values, as asymmetricaly 
distributed test results can lead to low reference 
values when calculated with the Bhattacharya 
methods (22). The C28-A3 guideline recommends 
using the direct method to establish and verify RIs 
(5) whenever possible. However, some authors fa-
vour the indirect method as the results are clinical-
ly relevant and much simpler for an individual lab-
oratory to implement than the time-consuming 
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ANALYTE (unit) Gender
PS MC R1 R2 R3 MEV
LL–UL LL–UL LL–UL LL–UL LL–UL LL–UL
ALP (U/L)
M 40–127 (*, #) 42–120 64–176 36–129 44–134 40–130
F 40–116 (*, #) 36–110 51–141 31–120 44–134 35–105
GGT (U/L)
M 9–58 (*, #) 11–58 6.5–34.1 8–61
F 7–32 (*, #) 7–27 6.0–26.4 5–36
AST (U/L)
M 9–28 (*, #) 13–36 10–45 12–32 5–40
F 9–24 (*, #) 11–28 9–32 10–28 5–32
ALT (U/L)
M 10–55 (*, #) 7–38 8–45 6–44 5–41
F 6–30 (*, #) 7–23 6–26 3–40 5–33
LDH (U/L)
M 104–212 (*, #) 126–231 190–364 135–225
F 105–202 (*, #) 120–231 190–364 135–214
AMY (U/L)
M 34–131 (*, #) 31–121 21–90
28–100
F 23–116 (*, #) 32–117 21–90
CK (U/L)
M 42–228 (*, #) 47–252 67–266 7–190
F 31–142 (*, #) 32–135 43–220 7–170
TG (mmol/L)
M 0.59–3.12 (*, #) 0.52–3.47 0.39–3.37 0.45–2.44 0.57–3.54
< 1.69‡
F 0.63–2.71 (*, #) 0.46–2.39 0.27–2.47 0.41–1.95 0.44–2.25
TC (mmol/L)
M 3.02–6.68 (*, #) 3.15–6.17 2.64–6.63 2.87–6.29 3.13–6.97
< 5.18‡
F 2.90–6.53 (*, #) 3.25–5.92 2.64–6.63 2.87–6.29 3.13–6.97
HDL–C (mmol/L)
M 0.54–1.30 (*, #) 0.77–1.57 0.77–1.39 0.73–1.74 0.8–1.71 > 1.5‡
F 0.72–2.02 (*, #) 0.92–1.97 0.80–2.15 0.91–2.15 0.91–2.02
LDL–C (mmol/L)
M 1.49–4.98 (*, #) 1.52–4.25 1.06–4.56 1.55–4.77 < 2.5‡
F 1.45–4.48 (*, #) 1.27–3.87 1.06–4.56 1.55–4.77
Ca (mmol/L)
M 2.1–2.5 2.17–2.5 2.20–2.60 2.28–2.64
2.15–2.55
F 2.1–2.5 2.12–2.47 2.18–2.63 2.16–2.57
IP (mmol/L)
M 0.76–1.51 0.76–1.4 0.74–1.52
0.8–1.45
F 0.85–1.39 (*, #) 0.83 – 1.4 0.74–1.52
Mg (mmol/L)
M 0.70–0.90 (*, #) 0.82–1.1 0.66–1.03
0.7–1.07
F 0.68–0.89 (*, #) 0.82–1.1 0.66–1.03
Fe (µmol/L )
M 8.5–30.1 (*, #) 7.3–31.1
5.83–34.5
F 5.2–27.8 (*, #) 4.9–30.1
TP (g/L)
M 62–79 (*) 67–82 61–80
66–87
F 62–78 (*) 66–82 61–80
ALB (g/L)
M 42–50 (#) 41–50 37–51
35–52
F 38–50 40–49 37–51
TBIL (µmol/L )
M 3.8–23.9 (*, #) 3.6–23.9 5.1–25.7
1.71–20.5
F 3.1–20.7 (*, #) 3.4–17.1 3.4–18.8
Table 5. Comparison of the present study data with previous RI studies
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ANALYTE (unit) Gender
PS MC R1 R2 R3 MEV
LL–UL LL–UL LL–UL LL–UL LL–UL LL–UL
DBIL (µmol/L )
M 1.20–5.30 (*, #) 1.71–8.50 1.71–10.26
1.54–5.13
F 1.10–4.60 (*, #) 1.71–6.84 0.68–7.01
GLU (mmol/L)
M 3.7–6.1  (#) 3.9–5.9 3.55–5.60 4.00–5.83
< 5.5‡
F 3.9–6.3 (*, #) 3.8–5.6 3.55–5.60 4.00–5.83
UN (mmol/L)
M 3.10–7.20 (*, #) 2.87–7.41 2.66–6.83 2.83–8.15 2.86–6.78 3.16–7.34
F 2.30–6.90 (*, #) 2.21–6.78 2.00–6.17 2.14–6.78 2.14–6.07 2.5–6.7
CRE (µmol/L )
M 59–107 (*, #) 58–89 62–133 80–142 71–101 62–106
F 45–83 (*, #) 51–69 44–106 62–115 56–92 44–80
UA (µmol/L )
M 202–489 (*, #) 213–476 160–350 220–480 202–417
F 148–369 (*, #) 148–363 60–240 130–380 143–339
Na (mmol/L)
M 134–147 137–144 133–151 139–147
136–145
F 134–146 137–144 133–151 139–147
K (mmol/L)
M 3.7–5.1 (*) 3.7–5.0 3.4–5.0 3.7-5.7
3.5–5.5
F 3.8–5.1 (#) 3.7–5.0 3.4–5.0 3.6-5.07
Cl (mmol/L)
M 96–108 98–107 97–108 103-111
98–107
F 98–108 100–107 97–108 103-111
FT3 (pmol/L)
M 3.7–6.0  (*, #) 2.00-6.77 4.57-8.02
3.1–6.8
F 3.1–6.2 (*, #) 2.00-6.77 4.57-8.02
FT4 (pmol/L)
M 11.9–20.4 (*, #) 10.29-24.45 13.2-25.0 12.00–21.93
F 11.3–20.9 (*, #) 10.29-24.45 13.2-25.0
TSH (mU/L)
M 0.36–4.78 (*, #) 0.51–3.51 0.30-4.17 0.60-6.25 0.27–4.2
F 0.49–4.92 (*, #) 0.51–3.51 0.30-4.17 0.60-6.25
VIT B12 (pmol/L)
M 70–368 (*, #) 158–1139 142-953
14 1–489
F 71–395 (*, #) 235–1473 142-953
FOL (nmol/L)
M 9–28 (*, #) 6.7–39.4 12.7-45.3
7.02–39.64
F 9–33 (*, #) 8.2–49.8 12.7-45.3
FER (µg/L)
M 46–399 (*, #) 10–190 30–400
F 15–209 (*, #) 3.2–56 13–150
PTH (pmol/L)
M 1.8–8.1 (*, #)
1.58–6.84





LL – lower limit, UL – upper limit, PS – present study, R1 – RIs investigated in the region of Bursa and presented by Ilcol and Aslan 
(19), R2 – RIs investigated in the region of Denizli by Enli et al. (20), R3 – RIs investigated in the region of Izmir by Koseoglu et al. (21), 
MC – global, multicenter RIs for Turkey (11), MEV – manufacturer expected values, M – male, F – female, (‡) – clinical decision limits 
for TG, TC, HDL-C, LDL-C and GLU, (*) – UL of PS different (> 10% lower or higher) from MC, R1, R2, R3 or MEV, (#) – LL of PS different 
(>10% lower or higher) from MC, R1, R2, R3 or MEV.
Table 5. Comparison of the present study data with previous RI studies (continued)
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direct a priori method (23,24). Furthermore, a re-
cent study has suggested that an indirect method 
can be as accurate as a direct method when the 
right indirect method is used (25). 
The exclusion criterion of more than one access 
per test to the laboratory during the data collec-
tion period has been applied in previous studies 
(23,24) and the rationale for that has been already 
explained. Approximately 20% of patient records 
were eliminated after applying this rule. The next 
exclusion rule (elimination of the data for hospital-
ized patients and for ambulatory patients from the 
intensive care unit) was applied to obtain a popu-
lation that could be labeled as outpatients so that 
the majority of the values for each analyte could 
be more health related. By applying this exclusion 
cascade, 37% of patient records were eliminated 
and the 5 million stored laboratory records were 
reduced to 1,366,948, refined records. This limita-
tion was balanced by the large amount of availa-
ble data, which allowed the production of gender-
specific RIs. Thus, the reference limits for many an-
alytes were calculated on sample sizes of several 
thousands of test results.
Our laboratory recently participated in the nation-
wide multicenter study of RI determination for the 
Turkish population by Ozarda et al. (11). Data from 
the present study extended the data obtained 
from the nationwide study in respect of the num-
ber of samples and parameters examined, by pro-
viding region-specific RIs for 34 biochemical ana-
lytes for males and females. The RIs observed for 
some analytes with the direct method were in 
good accordance with the reported RIs in the mul-
ticenter study in Turkey (11). However, noticeable 
differences were observed in the lower limits and/
or upper limits of ALT, LDH, TG, TC, HDL-C, LDL-C, 
Mg, TBIL, DBIL, GLU, CRE and K between the cur-
rent and the multicenter study (11). The differences 
between our regional data and the data of the 
multicenter study could firstly be attributed to dif-
ferences of analyzers and reagents. Abbott kits 
and analyzers were used in the multicenter study, 
whereas Roche kits and analyzers were used in the 
current study. In the multicenter study, the RIs 
were calculated using parametric and non-para-
metric methods. Since the RIs were derived by the 
non-parametric method in the present study, 
these were compared with those calculated by the 
non-parametric method in the multicenter study. 
However, the only difference for the calculation of 
the RIs between the two studies was the elimina-
tion of extreme values as outliers; the latent value 
exclusion method (17) in the multicenter study (11) 
and the Dixon range test (16) in the present study.
Comparisons were made with previous RI studies: 
Ilcol and Aslan, Enli et al. and Koseoglu et al. (19-
21). These studies have been abbreviated R1, R2 
and R3, respectively (Table 5). Differences were de-
termined in some of the lower limits and/or upper 
limits between the current direct RIs and those of 
the R1, R2 and R3 studies. These studies were per-
formed in different cities of Turkey using different 
analysers. R1, R2 and R3 were conducted in Bursa, 
Denizli and Izmir, respectively. The analysers were 
Technicon DAX-72 (Bayer Diagnostics, New York, 
USA) and ACS 180 (Bayer Diagnostics, New York, 
USA) for R1, ILAB 900 (Instrumentation Laboratory 
Company, Lexington, USA) and DPC Siemens Im-
mulite One (Siemens Healthcare Diagnostics, Los 
Angeles, USA) for R2 and Architect (Abbott Diag-
nostics, Wiesbaden, Germany) and Advia Centaur 
(Siemens Diagnostics, New York, USA) for R3. Tak-
en together, the instrumentation, the methodolo-
gy and the laboratory environment of the present 
study were different from these studies and all 
these differences may also be related to the differ-
ent characteristics (e.g. nutritional, environmental, 
economic and socio-cultural factors) of the popu-
lation used in the present study. 
For reproducibility and standardization, the pre-
analytical aspects must be accurately defined and 
described for the implementation of a multicenter 
RI study (10). Haemolysis is the most common pre-
analytical interference and still one of the biggest 
challenges to the laboratory specialists (26). There 
is clear evidence for clinically significant differenc-
es caused by visually undetectable to moderate 
hemolysis for LDH, AST, K and TBIL, whereas biases 
for some other parameters were found to be sta-
tistically significant, but remained within the con-
ventional Clinical Laboratory Improvement 
Amendments (CLIA) limits ALB, ALP, AMY, CL, HDL-
C, CK, GLU, Mg, TP, TG, unsaturated iron binding 
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capacity (UIBC) and UA (26). In addition, it is known 
that the storage temperature and the length of 
storage time have some effects on the samples 
(27). However, as a participant of the multicenter 
study, we carefully followed the SOPs and com-
mon protocol for all preanalytical aspects to stand-
ardization of the multicenter study and believe 
that these preanalytical effects are negligible for 
our study. Furthermore, the freezer has continu-
ous temperature recording. Based on this record-
ing, the serum samples were stored at -80 ± 2 oC 
for up to a maximum six months until analysis to 
minimize the effects of the storage temperature 
and the length of storage time.
In the present study, upper limits were found to be 
unexpectedly higher for some analytes, such as 
GGT, ALT and AST. However, the participants were 
excluded based on self-reported alcohol/tobacco 
consumption. There is a possibility that under-re-
porting of alcohol/tobacco consumption may 
have affected the data (e.g the upper limit of GGT). 
In addition, the enzyme analytes in this study are 
non-functional plasma enzymes and their lower 
limits have no diagnostic meaning, but upper lim-
its are critical from a diagnostic perspective. Thus, 
the differences in the lower limits of the enzymes 
between studies can be ignored. However, there is 
an exceptional condition that low values of ALP 
may indicate hypophosphatasia which is caused 
by deactivating mutations within the gene that 
encodes the tissue-nonspecific ALP characterized 
by deficiency of serum ALP with defective bone 
and teeth mineralization (28). A similar approach 
could also be applied to the lower limits of TG, TC, 
HDL-C, DBIL, UN, and CRE as these are also not crit-
ical for diagnosis. The upper reference limits de-
rived for GLU and lipid parameters in serum are 
not meant to be used for clinical decision-making, 
and it is therefore more appropriate to apply clini-
cal decision limits for these parameters in order to 
identify risk for certain diseases. 
It is known that Turks have a high prevalence of 
coronary heart disease, associated with some 
known risk factors. Turks have distinctively low 
concentrations of HDL-C, associated with elevated 
hepatic lipase activity and fasting triglyceridemia 
(29). Genetic and environmental factors are also 
important in modulating HDL-C concentrations in 
Turks (30). In the present study, the upper limits of 
HDL-C in males and females were 1.3 mmol/L and 
2.0 mmol/L, respectively. The upper limits of TG 
and TC in males and females were 3.12 mmol/L 
and 2.71 mmol/L, and 6.68 mmol/L and 6.53 
mmol/L, respectively. These values are compara-
ble to those reported for males and females living 
in other regions in Turkey (R1, R2, R3 and MC). Our 
data support previous studies on the risk factors 
and cardiovascular disease in Turkey. 
The findings of this study have shown that there 
are some differences in lower limits and/or upper 
limits between the direct method and the manu-
facturer’s expected values. From the total of 34 an-
alytes examined in the previous study, the lower 
limits and/or upper limits of 25 analytes were de-
termined as different (>10 lower or higher) using 
the direct method compared to the manufactur-
er’s expected values. The difficulties experienced 
by manufacturers when conducting appropriate 
RI studies must be taken into consideration and 
especially the challenge of accounting for poten-
tial differences in various patient populations. 
In summary, the data from the present study pro-
vide RIs for 34 biochemical analytes specific to our 
region (Erzurum). The observed RIs for the majori-
ty of analytes are comparable to the RIs reported 
recently by the nationwide multicenter RI study 
(11). The observed differences in lower limits and 
upper limits of some analytes may reflect regional 
characteristics of the population in Eastern Anato-
lia, and nutritional and environmental factors. The 
national study concluded that: “With the lack of re-
gional differences and the well-standardized sta-
tus of test results, the RIs derived from this nation-
wide study can be used for the entire Turkish pop-
ulation.” (11). Although we agree with this conclu-
sion in general, our data allow us to conclude that 
the region-specific RIs will provide detailed infor-
mation to better understand the health status of 
the locally served population.
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